TIL therapy - Pipeline Insight, 2022
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “TIL Therapy - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in TIL Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TIL Therapy: Overview
TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers and a growing list of other malignancies. TIL therapy essentially uses altered tumor cells to destroy the tumor itself. TILs, or tumor-infiltrating lymphocytes, are special immune system cells (T cells) that are naturally present inside some tumors. In TIL therapy, TILs are collected from the tumor during a biopsy, or surgical resection, and grown to very large numbers in a laboratory with interleukin-2 (IL-2), a protein that promotes rapid TIL growth. Once successfully grown to billions in number, the TILs are infused back into the patient, where they actively attack cancer cells while leaving healthy cells alone.
'TIL Therapy - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL Therapy pipeline landscape is provided which includes the disease overview and TIL Therapy treatment guidelines. The assessment part of the report embraces, in depth TIL Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the TIL Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIL Therapy Emerging Drugs
Further product details are provided in the report……..
TIL Therapy: Therapeutic Assessment
This segment of the report provides insights about the different TIL Therapy drugs segregated based on following parameters that define the scope of the report, such as:
TIL Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL Therapy drugs.
TIL Therapy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “TIL Therapy - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in TIL Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TIL Therapy: Overview
TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers and a growing list of other malignancies. TIL therapy essentially uses altered tumor cells to destroy the tumor itself. TILs, or tumor-infiltrating lymphocytes, are special immune system cells (T cells) that are naturally present inside some tumors. In TIL therapy, TILs are collected from the tumor during a biopsy, or surgical resection, and grown to very large numbers in a laboratory with interleukin-2 (IL-2), a protein that promotes rapid TIL growth. Once successfully grown to billions in number, the TILs are infused back into the patient, where they actively attack cancer cells while leaving healthy cells alone.
'TIL Therapy - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL Therapy pipeline landscape is provided which includes the disease overview and TIL Therapy treatment guidelines. The assessment part of the report embraces, in depth TIL Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TIL Therapy R&D. The therapies under development are focused on novel approaches to treat/improve TIL Therapy.
This segment of the TIL Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIL Therapy Emerging Drugs
- LN-145: Ivonace Biotherapeutics
- ITIL-168: Instil Bio
Further product details are provided in the report……..
TIL Therapy: Therapeutic Assessment
This segment of the report provides insights about the different TIL Therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in TIL Therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
TIL Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL Therapy drugs.
TIL Therapy Report Insights
- TIL Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing TIL Therapy drugs?
- How many TIL Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIL Therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIL Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TIL Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
TIL Therapy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIL Therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TIL Therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TIL Therapy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
LN-145: Ivonace Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ITIL-168: Instil Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIL Therapy Key Companies
TIL Therapy Key Products
TIL Therapy- Unmet Needs
TIL Therapy- Market Drivers and Barriers
TIL Therapy- Future Perspectives and Conclusion
TIL Therapy Analyst Views
TIL Therapy Key Companies
Appendix
Executive Summary
TIL Therapy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIL Therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TIL Therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TIL Therapy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
LN-145: Ivonace Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ITIL-168: Instil Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIL Therapy Key Companies
TIL Therapy Key Products
TIL Therapy- Unmet Needs
TIL Therapy- Market Drivers and Barriers
TIL Therapy- Future Perspectives and Conclusion
TIL Therapy Analyst Views
TIL Therapy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for TIL Therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for TIL Therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for TIL Therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for TIL Therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
